Company: HROW
Filing Date: 2025-10-01
Form Type: 8-K/A
Source: 0001493152-25-016473
Chunk: 1

Company: HARROW, INC.
Filing Date: 2025-10-01
Form: 8-K/A
Chunk 1
---
2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement                                                                      
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company ☐

If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Amendment No. 1 to the Current Report on Form 8-K of Harrow, Inc. (the “Company”) originally filed on September 26, 2025 (the “Original Report”) is being filed solely to file as exhibits the Agreement and Plan of Merger, dated September 24, 2025, by and among the Company, Harrow Acquisition Sub, Inc., Melt Pharmaceuticals, Inc. (“Melt”), and D. Brad Osborne as stockholder representative, and the related Milestone Payment Agreement, each of which were described in Item 1.01 of the Original Report. No other changes are being made to the Original Report.

For convenience, investors are reminded that the Original Report disclosed the Company’s entry into the Merger Agreement with Melt and noted that the Company expected to file the full text of the definitive agreements as an exhibit to its Quarterly Report on Form 10-Q for the three months ending September 30, 2025.

Item 9.01. Financial Statements and Exhibits to this Amendment No. 1

| (d)  
 2.1  
 10.1 |     | Exhibits                                                                                                                                                                                          
 Agreement and Plan of Merger, dated September 24, 2025, by and among Harrow, Inc., Harrow Acquisition Sub, Inc., Melt Pharmaceuticals, Inc., and D. Brad Osborne, as stockholder representative.* 
 Milestone Payment Agreement, dated September 24, 2025, by and between Harrow, Inc. and Melt Pharmaceuticals, Inc.*                                                                                |
|:-----|:----|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 104  |     | Cover                                                                                                                                                                                             
 Page Interactive Data File (embedded within